Shots:
- The company has initiated a P-III clinical study to evaluate the efficacy and safety of BAT2506 vs Simponi in ~ 480 volunteers with PsA. Simponi is approved for moderately to severely active RA, active PsA, active AS & UC
- BAT2506 is the 3rd proposed biosimilar of the company to enter a global P-III study
- Bio-Thera is developing other proposed biosimilars, including a bevacizumab & tocilizumab biosimilar that have completed P-III trial and is also pursuing biosimilar versions of ustekinumab, mepolizumab and dupilumab
Click here to read full press release/ article | Ref: Business Wire | Image: Business Wire
The post Bio-Thera Reports the Initiation of P-III Clinical Trial for BAT2506 (biosimilar, golimumab) first appeared on PharmaShots.
